[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"incontinence-urinary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:incontinence-urinary":223},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,73,96,130,165,194],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100467095",false,"NCT05362292","TReating Incontinence for Underlying Mental and Physical Health","Cognitive, Urinary, and Functional Trajectories of Older Women Using Pharmacologic Treatment Strategies for Urgency Incontinence","TRIUMPH","Inclusion Criteria:\n\n* Aged 60 years or older at the time of enrollment\n* Female sex at birth, without surgical or hormonal gender re-assignment therapy\n* Able to walk to the bathroom and use the toilet without assistance\n* Report urinary incontinence starting at least 3 months prior to screening\n* Report that at least half of incontinence episodes occur with a sudden or strong sensation of urgency\n* Report 2 or more urgency incontinence episodes over a 7-day period\n* Willing to provide informed consent and adhere to study procedures throughout the length of the study\n\nExclusion Criteria:\n\n* Prior clinician diagnosis of dementia, or a Montreal Cognitive Assessment (MOCA) score of 17 or lower on screening cognitive evaluation\n* Current use of anticholinergic, beta-3-adrenergic agonist, or other medication designed to improve urgency incontinence symptoms, or use in the past 1 month\n* Initiation, discontinuation, or dose change of dementia medications (such as donepezil, galantamine, memantine, rivastigmine) in the past 1 month (but candidates on stable doses are eligible)\n* Initiation, discontinuation, or dose change of other drugs with strong anticholinergic effects (based on the Beers List) in the past 1 month (but candidates on stable doses are eligible)\n* Initiation, discontinuation, or dose change of other drugs that can affect urinary frequency, including diuretics, in the past 1 month (but candidates on stable doses are eligible)\n* Current urinary tract infection (UTI) based on screening urinalysis and culture (but candidates can re-present for re-screening after undergoing treatment for UTI)\n* History of allergy or sensitivity to either of the study medications or an ingredient in the placebo or study medication capsule\n* Severe hepatic impairment (Child-Pugh score B or greater) or renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin) as a contraindication to both study medications\n* Current bladder obstruction or urinary retention (defined by symptoms suggesting difficulty emptying the bladder in addition to postvoid residual urine volume greater than 150 cc by portable bladder ultrasound)\n* Uncontrolled hypertension (based on measured systolic blood pressure greater than 180 or diastolic blood pressure greater than 110 mmHg) as a contraindication to beta-3-adrenergic therapy\n* Self-reported history of gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe ulcerative colitis, or toxic megacolon as contraindications for anticholinergic bladder therapy\n* Use of drugs with adverse interactions with one of the study medications in the past 1 month, including potent CYP3A4 inhibitors, hepatic enzyme metabolism inducers, narrow therapeutic index drugs metabolized by CYP2D6, or intention to start taking one of these medications during the study treatment period\n* History of bladder surgery, invasive intra-vesical therapy, or bulk bladder injections in the past 3 months (more remote surgery will not be exclusionary), or intention to undergo one of these procedures in the study treatment period\n* Use of other specialized incontinence therapy (electrostimulation, pelvic physiotherapy, formal behavioral therapy overseen by certified practitioners) in the past 3 months (more remote therapy will not be exclusionary), or intention to undergo one of these procedures in the study treatment period\n* Inability to sign informed consent or complete questionnaires, interviews, or study testing in English\n* Other condition that would prevent the participant from completing study procedures, in the opinion of the investigators (e.g., uncontrolled psychosis)",true,"FEMALE","60 Years",{"count":20,"type":21},270,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.",[27,28,29,30,31,32],"Urinary Incontinence, Urge","Urinary Incontinence","Overactive Bladder","Incontinence, Urge","Incontinence, Urinary","Incontinence","RECRUITING","2026-03-04",{"date":36,"type":37},"2026-03-06","ACTUAL",{"date":39,"type":37},"2022-10-04",{"date":41,"type":21},"2027-08-02",{"name":43,"class":44},"University of California, San Francisco","OTHER",2,{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":10,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100491922","NCT05685433","A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)","RECIPE","Inclusion Criteria:\n\n* Women and men above 18 years old with gender percentages reflective of disease prevalence in the U.S. population\n* Individual with diagnosis of overactive bladder with urgency urinary incontinence.\n* Individual has at least one urgency urinary incontinence episode on each of three days as determined on a 3-day voiding diary.\n* Individual gives written informed consent.\n* Individual is mentally competent and able to understand all study requirements.\n* Individual is willing and able to complete a 3-day voiding diary and quality of life questionnaire.\n* Individual is without pharmacological treatment of overactive bladder (anticholinergic and β3-adrenoceptor agonists) for 2 weeks prior to baseline or longer if the physician judges that the therapeutic effect is still present.\n* Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).\n* Individual is determined to be a suitable surgical candidate by physician.\n* Individual is appropriate for eCoin treatment based on the US FDA-approved IFU requirements.\n\nExclusion Criteria:\n\n* Individual is not appropriate for eCoin therapy based upon the US FDA-approved IFU requirements.\n* Individual has clinically significant bladder outlet obstruction. (Suspected bladder outlet obstruction will be initially assessed by uroflow study with those having a maximum flow rate \\\u003C 15mL\u002Fs requiring additional evaluation.)\n* Individual has predominantly stress urinary incontinence (greater than 1\u002F3 of leaks on baseline diary are stress).\n* Individual has an active urinary tract infection at time of enrollment.\n* Individual has known polyuria.\n* Individual has significant lower urinary tract pain or has been diagnosed with interstitial cystitis or bladder pain syndrome.\n* Individual has abnormal post void residual (i.e. greater than 200 cc initially and on repeat testing after double voiding)\n* Individual has clinically significant urethral stricture disease or bladder neck contracture. (Suspected disease or contracture will be initially assessed by uroflow study with those having a maximum flow rate \\\u003C 15mL\u002Fs requiring additional evaluation.)\n* Individual has chronic venous insufficiency with a history of skin change (hyperpigmentation, lipodermatosclerosis, ulceration) in the ankle region.\n* Individual has morbid obesity and in the opinion of the investigator is not a good candidate for the study.\n* Individual has had diagnosis of bladder, urethral, or prostate cancer.\n* Individual has had a prior anti-stress incontinence sling surgery within the last year.\n* Individual is pregnant or intends to become pregnant during the study.\n* Individual has the presence of urinary fistula, bladder stone, or interstitial cystitis.\n* Individual has uncontrolled diabetes mellitus (Hemoglobin A1C\\>7) or diabetes with significant peripheral complications. (Uncontrolled diabetes will be ruled out by blood test excluding those with Hemoglobin A1C\\>7).\n* Individual has an implantable neurostimulator, pacemaker, or implantable cardiac defibrillator (ICD).\n* Individual has been treated with onabotulinumtoxinA in the previous 9 months prior to enrollment, or more time if the principal investigator judges that the therapeutic effect is present.\n* Individual has been treated with percutaneous tibial nerve stimulation (PTNS) within the previous 4 weeks prior to enrollment or more time if the principal investigator judges that the therapeutic effect is present.\n* Individual is currently using transcutaneous electrical nerve stimulation (TENS) in the pelvic region, back, or legs.\n* Individual is aware that he or she will need an MRI scan other than a head\u002Fneck\u002Fshoulder MRI during the study period.\n* Individual has a clotting or bleeding disorder or is using anticoagulant therapies and in the opinion of the investigator is not a good candidate for the study (antiplatelet and anticoagulant therapy may be continued or held at the discretion of the investigator).\n* Individual is neutropenic or immune-compromised.\n* Individual has had previous surgery and\u002For significant scarring at the implant location.\n* Individual has ongoing dermatologic condition at the implant site, including but not limited to dermatitis and autoimmune disorders.\n* Individual has a clinically significant peripheral neuropathy in the lower extremities.\n* Individual has neurogenic bladder dysfunction.\n* Individual has pitting edema at implant location (≥ 2+ is excluded).\n* Individual has inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.\n* Individual has varicose veins and is symptomatic.\n* Individual has open wounds, trauma, or prior surgery in the lower extremities.\n* Individual has arterial disease in the lower extremities.\n* Individual has vasculitis in the lower extremities.\n* Individual has bladder stones or neoplasia. (Suspected bladder stones or neoplasia will be ruled out with a urine dipstick showing no more than trace blood, and microscopic analysis (which should be done in that case) shows ≥3 PBC's \u002FHPF unless that subject has been worked up and found negative for clinically significant disease such as malignant neoplasm or stones.)\n* In the opinion of the investigator, Individual is not a good candidate for participation in the study.","ALL","18 Years",{"count":55,"type":21},200,[57],"NA","A prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the eCoin® implanted tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).",[29,60,31,61],"Urge Incontinence","Urinary Urge Incontinence","2026-01-26",{"date":64,"type":37},"2026-01-28",{"date":66,"type":37},"2023-01-26",{"date":68,"type":21},"2031-12",{"name":70,"class":71},"Valencia Technologies Corporation","INDUSTRY",22,{"id":74,"slug":4,"hasResults":10,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":10,"sex":52,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100587139","NCT06924502","Testing the Protective and Caring Effect of a Water-in-oil Formulation in Patients Suffering From Urinary and\u002For Fecal Incontinence and Requiring Incontinence Care Products","Non-controlled, Exploratory, Single-arm Clinical Study With a Water-in-oil Emulsion to Test the Protecting and Caring Effect of the Formulation on 'Incontinence-care Product Requiring' Fecal and\u002For Urinary Incontinent Patients","Inclusion Criteria:\n\n* Patient is capable of understanding the information given to them and providing informed consent\n* 70 years of age and older\n* Patients with incontinence (fecal and\u002For urinary), requiring incontinence protection material\n* Skin type on Fitzpatrick scale: Between I to IV\n\nExclusion Criteria:\n\n* Current cancer treatment such as chemotherapy, irradiation\n* Documented allergies to skin care and \u002F or skin cleansing products\n* Wounds, moles, tattoos, scars, irritated skin, excessive hair growth, etc. at the test area that could influence the investigation\n* Incontinence-associated dermatitis (IAD) stage \\>1a\n* Active skin disease at the test area\n* Any topical medication at the test area within the last 3 days prior to the start of the study and \u002F or hroughout te entire course of the study\n* Mini-Mental-Status-Test (MMST) \\\u003C 20","70 Years",{"count":81,"type":21},40,[57],"The aim of this study is to test the protecting and caring effect of a protective balm on patients suffering from urinary and\u002For fecal incontinence and need incontinence care products.",[31,85],"Incontinence, Fecal","2025-07-17",{"date":88,"type":37},"2025-07-18",{"date":90,"type":37},"2025-06-06",{"date":92,"type":21},"2025-11",{"name":94,"class":71},"Dr. August Wolff GmbH & Co. KG Arzneimittel",1,{"id":97,"slug":4,"hasResults":10,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":16,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":95},"100556240","NCT06522529","Sumamos Excelencia Project: Implementation of Best Practices in Clinical Practice (Thrid Edition)","SUMAMOS EXCELENCIA Project: Assessment of Implementation of Best Practices in a National Health System (Thrid Edition)","SE24","Inclusion Criteria:\n\n1. Unit inclusion criteria:\n\n   * NHS units and nursing homes which voluntary adhere to the project.\n   * NHS units and nursing homes providing direct patient care and commit to implement evidence-based recommendations on hand hygiene and one of the following topics: pain assessment and management, urinary incontinence management, obesity prevention and breastfeeding promotion, Smoking Cessation, falls prevention, pressure injuries prevention. For the purposes of this study, a \"unit\" is defined as any service, centre or institution that delivers health services to a homogeneous group of patients who share similar characteristics.\n2. Patient inclusion criteria: The study will include all patients attended in the units participating in the study, who meet the following criteria, depending on the recommendations to be implemented in each unit:\n\n   1. Pain:\n\n      * People susceptible to suffering some type of pain regardless of age.\n      * Patients treated in acute or chronic health institutions (Hospitals, Nursing Homes or Primary Care).\n   2. Urinary incontinence:\n\n      \\- Patients 18 years or older.\n\n      \\- Patients with uncomplicated stress, urge or mixed urinary incontinence\n\n      \\- At least 7 days of admission or possibility of continuity of care preferably up to 6 weeks.\n   3. Obesity:\n\n      * Babies and preschool children up to 12 years old.\n      * For ages 2 to 12 years (inclusive), children must not be overweight or obese 1 year prior to baseline measurement (in February 2021 or at the closest review to February 2021 at which BMI is recorded).\n      * Good general health.\n   4. Breastfeeding:\n\n      * Lactating people.\n      * Healthy neonates of gestational age greater than 36 weeks, with birth weight greater than or equal to 2500 gr.\n      * Couples and relatives within the support network.\n      * Postpartum period and up to 6 months of life of the baby (183 days of life, included).\n      * In primary care, only non-urgent care will be included.\n   5. Smoking Cessation:\n\n      \\- ≥ 18 years of age\n      * Smokers\n   6. Pressure injury prevention:\n\n      \\- Adults population (≥ 18 years).\n      * Admitted to hospitals, nursing homes or included in home care programmes.\n      * Patients at risk of developing pressure injuries.\n   7. Falls prevention:\n\n      * Adults aged 65 years or older, and adults aged 18 years or older who may potentially present problems in walking as a result of neurological or traumatic diseases, medication, or who suffer from loss of strength or drowsiness.\n   8. Hand hygiene:\n\n      \\- All health professionals who care for patients in the units participating in the study.\n\n      Exclusion Criteria:\n\n      \\-",{"count":104,"type":21},400,[57],"There is a gap between research and clinical practice, leading to variability in decision-making. Multifaceted implementation strategies are for improving implementation of best practices. Quasi-experimental, multicentre, before and after. Primary care, hospital units and nursing homes, and the patients attended at both. Implementation of evidence-based recommendations by application of a multifaceted implementation strategy (training, audit, context analysis, local strategies design, feedback, facilitation). Data will be collected at baseline and, during the first year of follow up, at months (4,8,12)",[108,109,110,31,111,112,113],"Pain","Obesity, Childhood","Breast Feeding","Smoking Cessation","Pressure Injury","Fall",[115,116,117,118,119],"Implementation","Implementation science","Evidence-based practice","Nursing","Quality of Health Care","2024-07-24",{"date":122,"type":37},"2024-07-26",{"date":124,"type":21},"2024-09-01",{"date":126,"type":21},"2026-01-30",{"name":128,"class":129},"Instituto de Salud Carlos III","OTHER_GOV",{"id":131,"slug":4,"hasResults":10,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":16,"sex":52,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":141,"conditions":142,"keywords":150,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":95},"100517081","NCT06012903","Lower Urinary Tract Symptoms and School Functioning in Children","Epidemiological Study of Lower Urinary Tract Symptoms and School Functioning in Children in Regular Elementary School","Inclusion Criteria:\n\n* Children in 4th-6th grade\n* Parents whose children are in grades 1-6\n* Teachers responsible for teaching children in grades 1-6\n* Children who attend regular primary education\n* Capable of speaking \\& comprehending Dutch\n\nExclusion Criteria:\n\n* High school students\n* home-schooled children\n* children who attend special needs education\n* Language barrier to understanding Dutch","5 Years","12 Years",{"count":139,"type":21},250,"OBSERVATIONAL","Children in primary school often suffer from lower urinary tract symptoms (LUTS), which may negatively impact their overall well-being. Co-occurring neurodevelopmental disorders (NDDs) can adversely affect children as well and can cause restrictions in their daily life, especially in their school-environment.\n\nThe goal of this observational study is to identify the prevalence of LUTS in Flemish primary school children.The main questions it aims to answer are:\n\n* How prevalent are LUTS in regular primary education?\n* Is there a relation with well-being in school environment?\n* Is there an influence of co-occuring NDDs? Children, parents and teachers will be asked to fill in questionnaires related to this research question.",[143,144,31,145,146,147,148,149],"Lower Urinary Tract Symptoms","Neurodevelopmental Disorders","ADHD","ASD","Developmental Coordination Disorder","Child Development","Quality of Life",[151,152,153,154,155,156],"lower urinary tract symptoms","Quality of life","Pediatrics","neurodevelopmental disorders","VSSDES","DCD-Q","2024-07-12",{"date":159,"type":37},"2024-07-15",{"date":161,"type":37},"2022-10-06",{"date":90,"type":21},{"name":164,"class":44},"University Hospital, Ghent",{"id":166,"slug":4,"hasResults":10,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":16,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":173,"conditions":174,"keywords":183,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":95},"100550145","NCT06443268","Cerebrovascular Disease: Quality of Life (CODE: QoL)","CODE:QoL","Control group:\n\nInclusion criteria:\n\n* over 18 years old\n* No previous stroke OR previous stroke \\>3 years ago\n* No significant disability (maximum mRS 1)\n* ambulatory patients at the University Hospital of Zurich (USZ), Dept. of Neurology\n* Patients' AND caregiver's ability to give informed consent\n* Patients' AND close relative's \u002F caregiver's willingness to participate\n\nExclusion criteria:\n\n• Medication with steroid hormones (prednisone, prednisolone, dexamethasone, methylprednisolone, hydrocortisone etc.) within last 3 months\n\nMain Group:\n\nInclusion criteria:\n\n* over 18 years old\n* Patients diagnosed with either transient ischemic attack, ischemic stroke or intracerebral hemorrhage and their caregivers\n* Caregiver of a patient as described above, age over 18 years\n* Hospitalized or ambulatory patients at the University Hospital of Zurich (USZ) included within 28 days from event.\n* Patients' AND caregiver's ability to give informed consent\n* Patients' AND caregiver's willingness to participate\n\nExclusion criteria:\n\n• Medication with steroid hormones (prednisone, prednisolone, dexamethasone, methylprednisolone, hydrocortisone etc.) within last 3 months",{"count":172,"type":21},680,"The goal of this observational study is to learn about quality of life, stress and caregiver burden in patients with stroke and their caregivers.\n\nThe main question is:\n\n• to discover the factors associated with quality of life and stress in patient-caregiver dyads.\n\nParticipants will be asked to fill out questionnaires and agree to provide a hair sample (in order to measure stress hormones in hair) and consent to use of their routine clinical and laboratory data.\n\nResearchers will compare a group of participants without stroke to establish a comparable baseline.",[149,175,176,177,178,31,179,180,181,182],"Stroke, Acute","Sexual Behavior","Stress","Cortisol Excess","Caregiver Burden","Transient Ischemic Attack","Intracerebral Hemorrhage","Cerebrovascular Disorders",[184],"Stroke, QoL, HRQoL, Patient-Caregiver dyads, Stress, Burden","2024-05-29",{"date":187,"type":37},"2024-06-05",{"date":189,"type":37},"2023-05-27",{"date":191,"type":21},"2028-06-30",{"name":193,"class":44},"University of Zurich",{"id":195,"slug":4,"hasResults":10,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":10,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":208,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":45},"100385978","NCT04305743","Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A","Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A for Treatment of Overactive Bladder: a Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\n* Women \\>=18 years of age with diagnosis of urinary urgency, urinary frequency, urgency urinary incontinence, overactive bladder.\n* Procedure scheduled in either the outpatient clinic or the operating room to be performed without use of sedation, general, or neuraxial anesthesia.\n\nExclusion Criteria:\n\n* Male gender.\n* Women \\\u003C18 years of age.\n* Non-English speaking.\n* Pregnancy (patient will self-report pregnancy).\n* Participant has symptoms of overactive bladder due to any known neurological reason (e.g. spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc.)\n* Participant uses clean intermittent catheterization or indwelling catheter to manage urinary incontinence.\n* Participant has a history or current diagnosis of bladder cancer or other urothelial malignancy.\n* Participant has a known allergy or sensitivity to any botulinum toxin preparation.\n* Participant has any medical condition that may put her at increased risk with exposure to onabotulinumtoxin A, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis.\n* Participant is scheduled for administration of onabotulinumtoxin A with use of sedation, general, or neuraxial anesthesia.",{"count":201,"type":21},60,[24],"Currently, in clinical practice there has been no standardization in the number of injections a single dose of intradetrusor onabotulinumtoxin A is administered in. Given the increasing use of this treatment modality, the aim of this study is to compare outcomes for patients given a 100 unit dose of onabotulinumtoxin A split into 5 as compared to 20 injections for the treatment of overactive bladder or urgency urinary incontinence refractory to medical treatment.",[205,30,31,61,206,207],"Urinary Bladder, Overactive","Urinary Frequency More Than Once at Night","Nocturia",[209,210,211,212,213],"overactive bladder","urgency urinary incontinence","onabotulinumtoxin","bladder","botox","2020-11-03",{"date":216,"type":37},"2020-11-05",{"date":218,"type":37},"2019-10-09",{"date":220,"type":21},"2021-06-01",{"name":222,"class":44},"University of South Florida",""]